Abstract:BACKGROUND Diabetic nephropathy (DN) is the principal cause of end-stage renal disease. Previous studies have shown that clopidogrel can prevent the early progression of renal injury. AIM To elucidate whether clopidogrel is beneficial against DN by using a db / db mouse model. METHODS db/db mice with a higher urinary albumin/creatinine ratio (ACR) relative to age- and sex-matched wild-type control mice were randomly allocated to clopidogrel and vehicle treatment groups. Clopidogrel was administered at doses of 5, 10, and 20 mg/kg by gavage for 12 wk. Body mass, blood glucose level, and urinary creatinine and albumin concentrations in each group were measured before and after the intervention. Renal fibrosis was evaluated using periodic acid-Schiff and Masson's trichrome staining. The renal protein expression of tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and F4/80 was assessed using immunohistochemistry. Urinary TNF-α, monocyte chemoattractant protein-1 (MCP-1), and IL-6 levels were analyzed using enzyme-linked immunosorbent assay; TNF-α and IL-1β mRNA expression was measured using real-time quantitative polymerase chain reaction. The protein expression of fibronectin (FN) and collagen I was assessed using immunohistochemistry. RESULTS Clopidogrel treatment did not affect the body mass or blood glucose level of the db/db mice; however, it increased bleeding time and reduced urinary ACR in a dose-dependent manner. Immunohistochemical staining revealed an amelioration of renal fibrosis, significantly lower deposition of FN and collagen I, and significantly lower expression of the proinflammatory cytokines TNF-α and IL-1β and lower levels of urinary TNF-α and MCP-1 in the clopidogrel-treated db/db mice ( P < 0.05). Furthermore, clopidogrel significantly reduced macrophage infiltration into the glomeruli of the db/db mice. CONCLUSION Clopidogrel significantly reduced renal collagen deposition and fibrosis and prevented renal dysfunction in db / db mice, most likely through inhibition of renal macrophage infiltration and the associated inflammation. Key Words: Diabetes, Clopidogrel, Inflammation, Fibronectin, Diabetic nephropathy Core Tip: Diabetic nephropathy is the most common microvascular inflammatory disease among the diabetic complications. Previous studies have shown that clopidogrel administration is an effective means of suppressing inflammation in diseases such as acute myocardial infarction, diabetes, and acute ischemic cerebral infarction. In this study, we aimed to determine whether treatment with clopidogrel has a preventive or therapeutic effect in the kidneys of obese, type 2 diabetic db/db mice. In this experiment, we demonstrated that clopidogrel significantly reduced renal collagen deposition and fibrosis and prevented renal dysfunction in db/db mice, most likely through inhibition of renal macrophage infiltration and the associated inflammation. Citation: Li HQ, Liu N, Zheng ZY, Teng HL, Pei J. Clopidogrel delays and can reverse diabetic nephropathy pathogenesis in type 2 diabetic db/db mice. World J Diabetes 2022; 13(8): 600-612 URL: https://www.wjgnet.com/1948-9358/full/v13/i8/600.htm DOI: https://dx.doi.org/10.4239/wjd.v13.i8.600

Low-dose colchicine in type 2 diabetes with microalbuminuria: A double-blind randomized clinical trial

Low-Dose Colchicine in Patients With Type 2 Diabetes and Recent Myocardial Infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)

Association between Clinical Use of Colchicine and Risk of Type 2 Diabetes Mellitus among Gouty Patients: A Nationwide Cohort Study

Prevalence of macro- and microvascular complications in patients with type 2 diabetes and kidney disease with or without albuminuria in a single Chinese Diabetes Centre.

Colchicine use and the risk of CKD progression: a multicentre nested case-control study

In patients with type 2 diabetes and recent MI, colchicine reduced a composite CV outcome at 23 mo

Association of Low-Dose Colchicine With Incidence of Knee and Hip Replacements : Exploratory Analyses From a Randomized, Controlled, Double-Blind Trial

Low Ankle-Brachial Index is Associated with Early-Stage Chronic Kidney Disease in Type 2 Diabetic Patients Independent of Albuminuria.

Low-dose colchicine reduced risk for cardiovascular events in chronic coronary disease

Colchicine in Patients With Coronary Artery Disease: A Systematic Review and Meta-Analysis of Randomized Trials

Effect of different doses of colchicine on high sensitivity C-reactive protein in patients with acute minor stroke or transient ischemic attack: A pilot randomized controlled trial

Association of colchicine use with cardiovascular and limb events in peripheral artery disease: Insights from a retrospective cohort study

Meta-Analysis of Randomized Trials: Efficacy and Safety of Colchicine for Secondary Prevention of Cardiovascular Disease

SGLT2 Inhibitors Attenuate Nephrin Loss and Enhance TGF-β 1 Secretion in Type 2 Diabetes Patients with Albuminuria: a Randomized Clinical Trial

Diabetic Nephropathy Can Be Treated with Calcium Dobesilate by Alleviating the Chronic Inflammatory State and Improving Endothelial Cell Function

A meta-analysis evaluating efficacy and safety of colchicine for prevention of major cardiovascular events in patients with coronary artery disease

Safety and efficacy of colchicine in crystal-induced arthritis flare in 54 patients with severe chronic kidney disease

Colchicine in High-risk Patients with Acute Minor-to-moderate Ischemic Stroke or Transient Ischemic Attack (CHANCE-3): Rationale and design of a multicenter randomized placebo-controlled trial

Colchicine in diabetes mellitus

Clopidogrel delays and can reverse diabetic nephropathy pathogenesis in type 2 diabetic db/db mice

Colchicine treatment for the prevention of bare-metal stent restenosis in diabetic patients